SIGHTLINE ADVOCACY, LLC

Lobbying for AMGEN · Biotechnology

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · California · House · Senate · $20,000.00 income · posted Jan 20, 2026

Bills named in this filing 1

Lobbying activity 1

Health Issues

Issues related to drug pricing; H.R. 5526 - Biosimilar Red Tape Elimination Act

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.